Physician profile
Devi K Chettiar
NPI 1609198167
$676.34
in general payments reported to CMS, 2019-2025
15 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $88.93 · 2022: $181 · 2023: $132 · 2024: $119 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $406.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $139.11 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Regeneron Healthcare Solutions, INC. | $92.06 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $73.64 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $67.68 | 2021-2025 | |
| Incyte Corporation | $60.89 | 2021-2023 | Opzelura |
| Lilly USA, LLC | $44.01 | 2022-2024 | Taltz |
| Amgen INC. | $37.70 | 2022-2025 | Otezla |
| Novartis Pharmaceuticals Corporation | $33.18 | 2021-2023 | Cosentyx |
| E.R. Squibb & Sons, L.L.C. | $31.49 | 2023-2025 | Sotyktu |
| Abbvie INC. | $25.65 | 2024 | |
| Ucb, INC. | $22.01 | 2024 | Bimzelx |
| Kerecis Limited | $19.63 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Dermavant Sciences, INC. | $12.85 | 2023 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.15 | 2021 | |
| Biofrontera INC. | $5.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devi Chettiar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.